UNC alum, pharmaceutical exec Fred Eshelman makes another investment: experimental cancer treatment
Posted Apr 28, 2015
Fred Eshelman made another move by joining a group that invested $28 million in Innocrin Pharmaceuticals, a company developing treatments for breast and prostate cancers. Eshelman, who recently founded Eshelman Ventures, also joined Innocrin's board.
(Triangle Business Journal)
Related: Campus Connections
UNC Athletics Celebrates The Season With Team IMPACTCarolina Athletics welcomed members of Team IMPACT and their families for a fun-filled day of holiday activities with student-athletes from various programs on Saturday. The...
Tue Dec 16, 2025There Will Never Be Another Stuart Scott
For an entire generation of American sports fans, Stuart Scott loomed as large as the superstar athletes he covered. After 22 years at ESPN—bringing a...
Sun Dec 14, 2025
Meet UNC's Winter Commencement Graduates
After dedicating years to their studies, 1,444 Tar Heels will receive their Carolina diplomas at Winter Commencement on Sunday. UNC's December graduates excelled in the...
Sat Dec 13, 2025
Chansky’s Notebook: Game Changer
“Boo-Yah” to the Carolina guy who popularized the word. ESPN’s 30 for 30 special on Stuart Scott will make you laugh and wonder how he...
Thu Dec 11, 2025